TD Private Client Wealth LLC Sells 8,763 Shares of Sanofi (NASDAQ:SNY)

TD Private Client Wealth LLC cut its holdings in Sanofi (NASDAQ:SNY - Free Report) by 8.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 93,033 shares of the company's stock after selling 8,763 shares during the period. TD Private Client Wealth LLC's holdings in Sanofi were worth $4,487,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of SNY. Synergy Asset Management LLC purchased a new position in Sanofi in the fourth quarter valued at about $25,000. McClarren Financial Advisors Inc. lifted its stake in Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock valued at $28,000 after purchasing an additional 543 shares during the last quarter. Lee Danner & Bass Inc. purchased a new position in Sanofi in the fourth quarter valued at approximately $31,000. Sunbelt Securities Inc. grew its holdings in Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company's stock valued at $43,000 after purchasing an additional 313 shares during the period. Finally, Sierra Ocean LLC purchased a new stake in Sanofi in the fourth quarter worth $44,000. 14.04% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

SNY has been the topic of a number of recent research reports. Sanford C. Bernstein raised Sanofi to a "strong-buy" rating in a research report on Thursday, January 30th. The Goldman Sachs Group assumed coverage on shares of Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 price objective on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a research report on Thursday, January 30th. Finally, StockNews.com lowered shares of Sanofi from a "buy" rating to a "hold" rating in a research report on Thursday, December 12th. Three research analysts have rated the stock with a hold rating, one has given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $62.50.

Remove Ads

Sanofi Price Performance

SNY traded down $0.95 during trading on Wednesday, reaching $54.50. 3,002,569 shares of the company were exchanged, compared to its average volume of 2,271,820. Sanofi has a 12-month low of $45.22 and a 12-month high of $60.12. The company's 50-day moving average is $54.84 and its two-hundred day moving average is $52.82. The company has a quick ratio of 1.14, a current ratio of 1.46 and a debt-to-equity ratio of 0.15. The company has a market cap of $138.31 billion, a price-to-earnings ratio of 21.89, a P/E/G ratio of 1.01 and a beta of 0.58.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Research analysts forecast that Sanofi will post 4.36 earnings per share for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.